Geographic Atrophy Clinical Trials

15 recruiting

Frequently Asked Questions

Common questions about Geographic Atrophy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 1

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Geographic Atrophy
Hoffmann-La Roche132 enrolled16 locationsNCT06961370
Recruiting
Phase 1Phase 2

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Geographic Atrophy
Sanofi104 enrolled13 locationsNCT07215234
Recruiting
Phase 2

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

Geographic Atrophy
Genentech, Inc.60 enrolled17 locationsNCT05626114
Recruiting
Phase 2

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Geographic AtrophyMacular Degeneration
Janssen Research & Development, LLC274 enrolled104 locationsNCT06635148
Recruiting
Phase 1

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

Geographic Atrophy (GA)
Regeneron Pharmaceuticals54 enrolled4 locationsNCT07230834
Recruiting

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Geographic AtrophyMacular Degeneration
Astellas Pharma Global Development, Inc.1,000 enrolled64 locationsNCT06779773
Recruiting
Phase 4

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Geographic AtrophyAge-Related Macular Degeneration
Astellas Pharma Inc20 enrolled16 locationsNCT06970665
Recruiting
Phase 1Phase 2

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Geographic AtrophyAge-Related Macular Degeneration
AbbVie66 enrolled4 locationsNCT07160179
Recruiting
Phase 2

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Geographic Atrophy of the Macula
Galimedix Therapeutics Inc110 enrolled14 locationsNCT06659549
Recruiting
Phase 1Phase 2

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

Geographic AtrophyDry Age-Related Macular Degeneration
National Eye Institute (NEI)20 enrolled2 locationsNCT04339764
Recruiting
Phase 1Phase 2

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
Bionic Sight LLC40 enrolled1 locationNCT07158775
Recruiting
Phase 2

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Geographic Atrophy (GA)
ONL Therapeutics324 enrolled28 locationsNCT06659445
Recruiting
Phase 1Phase 2

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Geographic AtrophyAge-Related Macular DegenerationNon-neovascular AMD
Perceive Biotherapeutics, Inc.60 enrolled11 locationsNCT06087458
Recruiting

Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression

Geographic AtrophyAge-Related Macular Degeneration
Medical University of Vienna200 enrolled7 locationsNCT06351657
Recruiting

A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

Geographic AtrophyMacular DegenerationStargardt Disease
Nanoscope Therapeutics Inc.30 enrolled1 locationNCT06805474
Recruiting

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

Retinitis PigmentosaStargardt DiseaseRetinal Dystrophies+4 more
Ray Therapeutics, Inc.120 enrolled1 locationNCT06375239
Recruiting
Not Applicable

Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

Geographic AtrophyAge-Related Macular Degeneration
VisionCare, Inc.125 enrolled10 locationsNCT05438732
Recruiting
Phase 1Phase 2

Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.

Geographic AtrophyAge-Related Macular DegenerationMacular Degeneration+2 more
Eyestem Research Pvt. Ltd.54 enrolled3 locationsNCT06394232